Patents by Inventor Louise Hjerrild Zeuthen

Louise Hjerrild Zeuthen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bioassay for insulin formulations
    Patent number: 10914728
    Abstract: The invention relates to a bioassay of insulin peptide in oral formulations and low affinity insulin peptides in liquid formulations, by for quantifying phosphorylated Akt, thereby avoiding the interference of excipients in potency determination.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: February 9, 2021
    Assignee: Novo Nordisk A/S
    Inventors: Louise Hjerrild Zeuthen, Jan Amstrup, Thomas Aaskov Pedersen
  • Bioassay for Insulin formulations
    Publication number: 20190361007
    Abstract: The invention relates to a bioassay of insulin peptide in oral formulations and low affinity insulin peptides in liquid formulations, by for quantifying phosphorylated Akt, thereby avoiding the interference of excipients in potency determination.
    Type: Application
    Filed: October 24, 2017
    Publication date: November 28, 2019
    Inventors: Louise Hjerrild Zeuthen, Jan Amstrup, Thomas Aaskov Pedersen
  • OSCAR ANTAGONISTS
    Publication number: 20140056918
    Abstract: The present invention relates to antagonistic OSCAR ligands. The present invention furthermore relates to use of such ligands.
    Type: Application
    Filed: October 30, 2013
    Publication date: February 27, 2014
    Inventors: Li Guo, Svetlana Panina, Jesper Pass, Louise Hjerrild Zeuthen, Louise Maymann Nitze
  • THERAPEUTIC ANTIBODIES
    Publication number: 20130295116
    Abstract: The present invention concerns human antibodies recognising the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro-inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders.
    Type: Application
    Filed: June 18, 2013
    Publication date: November 7, 2013
    Inventors: Stefan Zahn, Louise Hjerrild Zeuthen, Anker Jon Hansen, Kristian Kjaergaard, Soeren Lund
  • THERAPEUTIC ANTIBODIES
    Publication number: 20130004514
    Abstract: The present invention concerns human antibodies recognising the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro-inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders.
    Type: Application
    Filed: June 6, 2012
    Publication date: January 3, 2013
    Applicant: Novo Nordisk A/S
    Inventors: Stefan Zahn, Louise Hjerrild Zeuthen, Anker Jon Hansen, Kristian Kjaergaard, Soeren Lund